PubMed:10704524
Annnotations
Glycan-Motif
{"project":"Glycan-Motif","denotations":[{"id":"T1","span":{"begin":752,"end":759},"obj":"https://glytoucan.org/Structures/Glycans/G70323CJ"},{"id":"T2","span":{"begin":1034,"end":1040},"obj":"https://glytoucan.org/Structures/Glycans/G82576YO"},{"id":"T3","span":{"begin":1131,"end":1142},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T4","span":{"begin":1454,"end":1461},"obj":"https://glytoucan.org/Structures/Glycans/G70323CJ"},{"id":"T5","span":{"begin":1573,"end":1580},"obj":"https://glytoucan.org/Structures/Glycans/G70323CJ"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlyCosmos6-Glycan-Motif-Image
{"project":"GlyCosmos6-Glycan-Motif-Image","denotations":[{"id":"T1","span":{"begin":752,"end":759},"obj":"Glycan_Motif"},{"id":"T2","span":{"begin":1034,"end":1040},"obj":"Glycan_Motif"},{"id":"T3","span":{"begin":1131,"end":1142},"obj":"Glycan_Motif"},{"id":"T4","span":{"begin":1454,"end":1461},"obj":"Glycan_Motif"},{"id":"T5","span":{"begin":1573,"end":1580},"obj":"Glycan_Motif"}],"attributes":[{"id":"A1","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ"},{"id":"A2","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G82576YO"},{"id":"A3","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G81533KY"},{"id":"A4","pred":"image","subj":"T4","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ"},{"id":"A5","pred":"image","subj":"T5","obj":"https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G70323CJ"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
sentences
{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":97},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":98,"end":293},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":294,"end":436},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":437,"end":502},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":503,"end":802},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":803,"end":964},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":965,"end":1152},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1153,"end":1241},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1242,"end":1441},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1442,"end":1677},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1678,"end":2032},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":97},"obj":"Sentence"},{"id":"T2","span":{"begin":98,"end":293},"obj":"Sentence"},{"id":"T3","span":{"begin":294,"end":436},"obj":"Sentence"},{"id":"T4","span":{"begin":437,"end":502},"obj":"Sentence"},{"id":"T5","span":{"begin":503,"end":802},"obj":"Sentence"},{"id":"T6","span":{"begin":803,"end":964},"obj":"Sentence"},{"id":"T7","span":{"begin":965,"end":1152},"obj":"Sentence"},{"id":"T8","span":{"begin":1153,"end":1241},"obj":"Sentence"},{"id":"T9","span":{"begin":1242,"end":1441},"obj":"Sentence"},{"id":"T10","span":{"begin":1442,"end":1677},"obj":"Sentence"},{"id":"T11","span":{"begin":1678,"end":2032},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":97},"obj":"Sentence"},{"id":"T2","span":{"begin":98,"end":293},"obj":"Sentence"},{"id":"T3","span":{"begin":294,"end":436},"obj":"Sentence"},{"id":"T4","span":{"begin":437,"end":502},"obj":"Sentence"},{"id":"T5","span":{"begin":503,"end":802},"obj":"Sentence"},{"id":"T6","span":{"begin":803,"end":964},"obj":"Sentence"},{"id":"T7","span":{"begin":965,"end":1152},"obj":"Sentence"},{"id":"T8","span":{"begin":1153,"end":1241},"obj":"Sentence"},{"id":"T9","span":{"begin":1242,"end":1441},"obj":"Sentence"},{"id":"T10","span":{"begin":1442,"end":1677},"obj":"Sentence"},{"id":"T11","span":{"begin":1678,"end":2032},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlyCosmos6-Glycan-Motif-Structure
{"project":"GlyCosmos6-Glycan-Motif-Structure","denotations":[{"id":"T1","span":{"begin":752,"end":759},"obj":"https://glytoucan.org/Structures/Glycans/G70323CJ"},{"id":"T2","span":{"begin":1034,"end":1040},"obj":"https://glytoucan.org/Structures/Glycans/G82576YO"},{"id":"T3","span":{"begin":1131,"end":1142},"obj":"https://glytoucan.org/Structures/Glycans/G81533KY"},{"id":"T4","span":{"begin":1454,"end":1461},"obj":"https://glytoucan.org/Structures/Glycans/G70323CJ"},{"id":"T5","span":{"begin":1573,"end":1580},"obj":"https://glytoucan.org/Structures/Glycans/G70323CJ"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlycoBiology-FMA
{"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":12,"end":37},"obj":"FMAID:196780"},{"id":"_T2","span":{"begin":12,"end":37},"obj":"FMAID:82786"},{"id":"_T3","span":{"begin":80,"end":96},"obj":"FMAID:196731"},{"id":"_T4","span":{"begin":80,"end":96},"obj":"FMAID:82742"},{"id":"_T5","span":{"begin":110,"end":135},"obj":"FMAID:82786"},{"id":"_T6","span":{"begin":110,"end":135},"obj":"FMAID:196780"},{"id":"_T7","span":{"begin":171,"end":184},"obj":"FMAID:196789"},{"id":"_T8","span":{"begin":171,"end":184},"obj":"FMAID:82794"},{"id":"_T9","span":{"begin":195,"end":204},"obj":"FMAID:162299"},{"id":"_T10","span":{"begin":195,"end":204},"obj":"FMAID:63836"},{"id":"_T11","span":{"begin":242,"end":264},"obj":"FMAID:82786"},{"id":"_T12","span":{"begin":242,"end":264},"obj":"FMAID:196780"},{"id":"_T13","span":{"begin":277,"end":292},"obj":"FMAID:82782"},{"id":"_T14","span":{"begin":277,"end":292},"obj":"FMAID:196776"},{"id":"_T15","span":{"begin":536,"end":551},"obj":"FMAID:82742"},{"id":"_T16","span":{"begin":536,"end":551},"obj":"FMAID:196731"},{"id":"_T17","span":{"begin":619,"end":624},"obj":"FMAID:7209"},{"id":"_T18","span":{"begin":619,"end":624},"obj":"FMAID:93687"},{"id":"_T19","span":{"begin":625,"end":630},"obj":"FMAID:68646"},{"id":"_T20","span":{"begin":625,"end":630},"obj":"FMAID:169002"},{"id":"_T21","span":{"begin":752,"end":759},"obj":"FMAID:82801"},{"id":"_T22","span":{"begin":752,"end":759},"obj":"FMAID:196796"},{"id":"_T23","span":{"begin":785,"end":801},"obj":"FMAID:196731"},{"id":"_T24","span":{"begin":785,"end":801},"obj":"FMAID:82742"},{"id":"_T25","span":{"begin":998,"end":1015},"obj":"FMAID:196731"},{"id":"_T26","span":{"begin":998,"end":1015},"obj":"FMAID:82742"},{"id":"_T27","span":{"begin":1004,"end":1015},"obj":"FMAID:82744"},{"id":"_T28","span":{"begin":1004,"end":1015},"obj":"FMAID:196733"},{"id":"_T29","span":{"begin":1034,"end":1040},"obj":"FMAID:196784"},{"id":"_T30","span":{"begin":1034,"end":1040},"obj":"FMAID:82790"},{"id":"_T31","span":{"begin":1064,"end":1080},"obj":"FMAID:196731"},{"id":"_T32","span":{"begin":1064,"end":1080},"obj":"FMAID:82742"},{"id":"_T33","span":{"begin":1181,"end":1198},"obj":"FMAID:196731"},{"id":"_T34","span":{"begin":1181,"end":1198},"obj":"FMAID:82742"},{"id":"_T35","span":{"begin":1187,"end":1198},"obj":"FMAID:196733"},{"id":"_T36","span":{"begin":1187,"end":1198},"obj":"FMAID:82744"},{"id":"_T37","span":{"begin":1274,"end":1289},"obj":"FMAID:196731"},{"id":"_T38","span":{"begin":1274,"end":1289},"obj":"FMAID:82742"},{"id":"_T39","span":{"begin":1373,"end":1379},"obj":"FMAID:30332"},{"id":"_T40","span":{"begin":1373,"end":1379},"obj":"FMAID:171168"},{"id":"_T41","span":{"begin":1454,"end":1461},"obj":"FMAID:82801"},{"id":"_T42","span":{"begin":1454,"end":1461},"obj":"FMAID:196796"},{"id":"_T43","span":{"begin":1462,"end":1478},"obj":"FMAID:82742"},{"id":"_T44","span":{"begin":1462,"end":1478},"obj":"FMAID:196731"},{"id":"_T45","span":{"begin":1573,"end":1580},"obj":"FMAID:196796"},{"id":"_T46","span":{"begin":1573,"end":1580},"obj":"FMAID:82801"},{"id":"_T47","span":{"begin":1581,"end":1597},"obj":"FMAID:82742"},{"id":"_T48","span":{"begin":1581,"end":1597},"obj":"FMAID:196731"},{"id":"_T49","span":{"begin":1696,"end":1711},"obj":"FMAID:82742"},{"id":"_T50","span":{"begin":1696,"end":1711},"obj":"FMAID:196731"},{"id":"_T51","span":{"begin":1749,"end":1762},"obj":"FMAID:82794"},{"id":"_T52","span":{"begin":1749,"end":1762},"obj":"FMAID:196789"},{"id":"_T53","span":{"begin":1865,"end":1882},"obj":"FMAID:165838"},{"id":"_T54","span":{"begin":1865,"end":1882},"obj":"FMAID:63843"},{"id":"_T55","span":{"begin":1865,"end":1882},"obj":"FMAID:62316"},{"id":"_T56","span":{"begin":1865,"end":1882},"obj":"FMAID:162310"},{"id":"_T57","span":{"begin":1950,"end":1954},"obj":"FMAID:217859"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
uniprot-human
{"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":6,"end":37},"obj":"http://www.uniprot.org/uniprot/P17050"},{"id":"T2","span":{"begin":104,"end":135},"obj":"http://www.uniprot.org/uniprot/P17050"},{"id":"T3","span":{"begin":165,"end":186},"obj":"http://www.uniprot.org/uniprot/P17050"},{"id":"T4","span":{"begin":1743,"end":1764},"obj":"http://www.uniprot.org/uniprot/P06280"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
uniprot-mouse
{"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":6,"end":37},"obj":"http://www.uniprot.org/uniprot/Q9QWR8"},{"id":"T2","span":{"begin":104,"end":135},"obj":"http://www.uniprot.org/uniprot/Q9QWR8"},{"id":"T3","span":{"begin":165,"end":186},"obj":"http://www.uniprot.org/uniprot/Q9QWR8"},{"id":"T4","span":{"begin":1480,"end":1483},"obj":"http://www.uniprot.org/uniprot/A2APV2"},{"id":"T5","span":{"begin":1743,"end":1764},"obj":"http://www.uniprot.org/uniprot/P51569"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlycoBiology-NCBITAXON
{"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":625,"end":630},"obj":"http://purl.bioontology.org/ontology/STY/T025"},{"id":"T2","span":{"begin":647,"end":660},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/691256"},{"id":"T3","span":{"begin":647,"end":660},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/1113441"},{"id":"T4","span":{"begin":1782,"end":1789},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/353209"},{"id":"T5","span":{"begin":1865,"end":1882},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/177873"},{"id":"T6","span":{"begin":1865,"end":1882},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/177875"},{"id":"T7","span":{"begin":1865,"end":1882},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/177872"},{"id":"T8","span":{"begin":1865,"end":1882},"obj":"http://purl.bioontology.org/ontology/NCBITAXON/177874"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GO-BP
{"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":110,"end":142},"obj":"http://purl.obolibrary.org/obo/GO_0008456"},{"id":"T2","span":{"begin":165,"end":184},"obj":"http://purl.obolibrary.org/obo/GO_0004557"},{"id":"T3","span":{"begin":1743,"end":1762},"obj":"http://purl.obolibrary.org/obo/GO_0004557"},{"id":"T4","span":{"begin":165,"end":186},"obj":"http://purl.obolibrary.org/obo/GO_0008456"},{"id":"T5","span":{"begin":402,"end":415},"obj":"http://purl.obolibrary.org/obo/GO_0070085"},{"id":"T6","span":{"begin":570,"end":578},"obj":"http://purl.obolibrary.org/obo/GO_0046903"},{"id":"T7","span":{"begin":1086,"end":1096},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T8","span":{"begin":1357,"end":1367},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T9","span":{"begin":1419,"end":1429},"obj":"http://purl.obolibrary.org/obo/GO_0097503"},{"id":"T10","span":{"begin":1295,"end":1309},"obj":"http://purl.obolibrary.org/obo/GO_0016310"},{"id":"T11","span":{"begin":1400,"end":1414},"obj":"http://purl.obolibrary.org/obo/GO_0016310"},{"id":"T12","span":{"begin":1603,"end":1617},"obj":"http://purl.obolibrary.org/obo/GO_0016310"},{"id":"T13","span":{"begin":1958,"end":1970},"obj":"http://purl.obolibrary.org/obo/GO_0009058"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GO-CC
{"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":195,"end":204},"obj":"http://purl.obolibrary.org/obo/GO_0005764"},{"id":"T2","span":{"begin":625,"end":630},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T3","span":{"begin":1022,"end":1026},"obj":"http://purl.obolibrary.org/obo/GO_0019013"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
EDAM-topics
{"project":"EDAM-topics","denotations":[{"id":"T1","span":{"begin":0,"end":5},"obj":"http://edamontology.org/topic_2815"},{"id":"T2","span":{"begin":98,"end":103},"obj":"http://edamontology.org/topic_2815"},{"id":"T3","span":{"begin":195,"end":204},"obj":"http://edamontology.org/topic_0616"},{"id":"T4","span":{"begin":306,"end":313},"obj":"http://edamontology.org/topic_3678"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
EDAM-DFO
{"project":"EDAM-DFO","denotations":[{"id":"T1","span":{"begin":58,"end":67},"obj":"http://edamontology.org/data_0883"},{"id":"T2","span":{"begin":552,"end":562},"obj":"http://edamontology.org/data_0883"},{"id":"T3","span":{"begin":661,"end":671},"obj":"http://edamontology.org/data_0883"},{"id":"T4","span":{"begin":815,"end":825},"obj":"http://edamontology.org/data_0883"},{"id":"T5","span":{"begin":911,"end":921},"obj":"http://edamontology.org/data_0883"},{"id":"T6","span":{"begin":1022,"end":1033},"obj":"http://edamontology.org/data_1313"},{"id":"T7","span":{"begin":1143,"end":1151},"obj":"http://edamontology.org/data_1756"},{"id":"T8","span":{"begin":1333,"end":1343},"obj":"http://edamontology.org/data_0883"},{"id":"T9","span":{"begin":1430,"end":1440},"obj":"http://edamontology.org/data_0883"},{"id":"T10","span":{"begin":1678,"end":1688},"obj":"http://edamontology.org/operation_2424"},{"id":"T11","span":{"begin":1712,"end":1722},"obj":"http://edamontology.org/data_0883"},{"id":"T12","span":{"begin":1931,"end":1940},"obj":"http://edamontology.org/data_0883"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
NGLY1-deficiency
{"project":"NGLY1-deficiency","denotations":[{"id":"PD-NGLY1-deficiency-B_T1","span":{"begin":1219,"end":1225},"obj":"chem:24139"},{"id":"PD-NGLY1-deficiency-B_T2","span":{"begin":1234,"end":1240},"obj":"chem:24139"},{"id":"PD-NGLY1-deficiency-B_T3","span":{"begin":1488,"end":1494},"obj":"chem:24139"}],"namespaces":[{"prefix":"hgnc","uri":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:"},{"prefix":"omim","uri":"https://www.omim.org/entry/"},{"prefix":"chem","uri":"https://pubchem.ncbi.nlm.nih.gov/compound/"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlycoBiology-MAT
{"project":"GlycoBiology-MAT","denotations":[{"id":"T1","span":{"begin":1373,"end":1379},"obj":"http://purl.obolibrary.org/obo/MAT_0000488"},{"id":"T2","span":{"begin":1865,"end":1882},"obj":"http://purl.obolibrary.org/obo/MAT_0000346"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlycoBiology-Motifs
{"project":"GlycoBiology-Motifs","denotations":[{"id":"T1","span":{"begin":747,"end":759},"obj":"http://rdf.glycoinfo.org/glycan/G00028MO"},{"id":"T2","span":{"begin":1449,"end":1461},"obj":"http://rdf.glycoinfo.org/glycan/G00028MO"},{"id":"T3","span":{"begin":1568,"end":1580},"obj":"http://rdf.glycoinfo.org/glycan/G00028MO"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
Lectin
{"project":"Lectin","denotations":[{"id":"Lectin_T1","span":{"begin":1480,"end":1483},"obj":"https://acgg.asia/db/lfdb/LfDB0217"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlyTouCan-IUPAC
{"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T2","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T3","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T4","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T5","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T6","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T7","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T8","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T9","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T10","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T11","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T12","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T13","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T14","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T15","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T16","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T17","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T18","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T19","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T20","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T21","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T22","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T23","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T24","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T25","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T26","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T27","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T28","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T29","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T30","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T31","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T32","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T33","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T34","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T35","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T36","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T37","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T38","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T39","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T40","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T41","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T42","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T43","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T44","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T45","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T46","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T47","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T48","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T49","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T50","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T51","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T52","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T53","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T54","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T55","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T56","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T57","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T58","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T59","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T60","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T61","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T62","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T63","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T64","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T65","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T66","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T67","span":{"begin":143,"end":149},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T68","span":{"begin":1732,"end":1738},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T69","span":{"begin":1849,"end":1855},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T70","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G44384WF\""},{"id":"GlycanIUPAC_T71","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G44384WF\""},{"id":"GlycanIUPAC_T72","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G37452RG\""},{"id":"GlycanIUPAC_T73","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G37452RG\""},{"id":"GlycanIUPAC_T74","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G56296FC\""},{"id":"GlycanIUPAC_T75","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G56296FC\""},{"id":"GlycanIUPAC_T76","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G44877OG\""},{"id":"GlycanIUPAC_T77","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G44877OG\""},{"id":"GlycanIUPAC_T78","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G22627HB\""},{"id":"GlycanIUPAC_T79","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G22627HB\""},{"id":"GlycanIUPAC_T80","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G76069IP\""},{"id":"GlycanIUPAC_T81","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G76069IP\""},{"id":"GlycanIUPAC_T82","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G77301LL\""},{"id":"GlycanIUPAC_T83","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G77301LL\""},{"id":"GlycanIUPAC_T84","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G92446EV\""},{"id":"GlycanIUPAC_T85","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G92446EV\""},{"id":"GlycanIUPAC_T86","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G93798MG\""},{"id":"GlycanIUPAC_T87","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G93798MG\""},{"id":"GlycanIUPAC_T88","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G19180VS\""},{"id":"GlycanIUPAC_T89","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G19180VS\""},{"id":"GlycanIUPAC_T90","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G00261CT\""},{"id":"GlycanIUPAC_T91","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G00261CT\""},{"id":"GlycanIUPAC_T92","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G23925MM\""},{"id":"GlycanIUPAC_T93","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G23925MM\""},{"id":"GlycanIUPAC_T94","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G27176LA\""},{"id":"GlycanIUPAC_T95","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G27176LA\""},{"id":"GlycanIUPAC_T96","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G76226NF\""},{"id":"GlycanIUPAC_T97","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G76226NF\""},{"id":"GlycanIUPAC_T98","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G80006GG\""},{"id":"GlycanIUPAC_T99","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G80006GG\""},{"id":"GlycanIUPAC_T100","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G99968MY\""},{"id":"GlycanIUPAC_T101","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G99968MY\""},{"id":"GlycanIUPAC_T102","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G67393MB\""},{"id":"GlycanIUPAC_T103","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G67393MB\""},{"id":"GlycanIUPAC_T104","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G09037VU\""},{"id":"GlycanIUPAC_T105","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G09037VU\""},{"id":"GlycanIUPAC_T106","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G19508PX\""},{"id":"GlycanIUPAC_T107","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G19508PX\""},{"id":"GlycanIUPAC_T108","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G40619ZS\""},{"id":"GlycanIUPAC_T109","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G40619ZS\""},{"id":"GlycanIUPAC_T110","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G19507SX\""},{"id":"GlycanIUPAC_T111","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G19507SX\""},{"id":"GlycanIUPAC_T112","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G50874XT\""},{"id":"GlycanIUPAC_T113","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G50874XT\""},{"id":"GlycanIUPAC_T114","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G60561GL\""},{"id":"GlycanIUPAC_T115","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G60561GL\""},{"id":"GlycanIUPAC_T116","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G98788DE\""},{"id":"GlycanIUPAC_T117","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G98788DE\""},{"id":"GlycanIUPAC_T118","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G85696MX\""},{"id":"GlycanIUPAC_T119","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G85696MX\""},{"id":"GlycanIUPAC_T120","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G82652IN\""},{"id":"GlycanIUPAC_T121","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G82652IN\""},{"id":"GlycanIUPAC_T122","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G95603AK\""},{"id":"GlycanIUPAC_T123","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G95603AK\""},{"id":"GlycanIUPAC_T124","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G87993NJ\""},{"id":"GlycanIUPAC_T125","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G87993NJ\""},{"id":"GlycanIUPAC_T126","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G85533KK\""},{"id":"GlycanIUPAC_T127","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G85533KK\""},{"id":"GlycanIUPAC_T128","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G78142NX\""},{"id":"GlycanIUPAC_T129","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G78142NX\""},{"id":"GlycanIUPAC_T130","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G94944YR\""},{"id":"GlycanIUPAC_T131","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G94944YR\""},{"id":"GlycanIUPAC_T132","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G60875EM\""},{"id":"GlycanIUPAC_T133","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G60875EM\""},{"id":"GlycanIUPAC_T134","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G58390SD\""},{"id":"GlycanIUPAC_T135","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G58390SD\""},{"id":"GlycanIUPAC_T136","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G46314WZ\""},{"id":"GlycanIUPAC_T137","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G46314WZ\""},{"id":"GlycanIUPAC_T138","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G35012MY\""},{"id":"GlycanIUPAC_T139","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G35012MY\""},{"id":"GlycanIUPAC_T140","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G11847VZ\""},{"id":"GlycanIUPAC_T141","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G11847VZ\""},{"id":"GlycanIUPAC_T142","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G91662AB\""},{"id":"GlycanIUPAC_T143","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G91662AB\""},{"id":"GlycanIUPAC_T144","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G99771WN\""},{"id":"GlycanIUPAC_T145","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G99771WN\""},{"id":"GlycanIUPAC_T146","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G92389SI\""},{"id":"GlycanIUPAC_T147","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G92389SI\""},{"id":"GlycanIUPAC_T148","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G40437FC\""},{"id":"GlycanIUPAC_T149","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G40437FC\""},{"id":"GlycanIUPAC_T150","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G00509WV\""},{"id":"GlycanIUPAC_T151","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G00509WV\""},{"id":"GlycanIUPAC_T152","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G36565LB\""},{"id":"GlycanIUPAC_T153","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G36565LB\""},{"id":"GlycanIUPAC_T154","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G50335BH\""},{"id":"GlycanIUPAC_T155","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G50335BH\""},{"id":"GlycanIUPAC_T156","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G87946UV\""},{"id":"GlycanIUPAC_T157","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G87946UV\""},{"id":"GlycanIUPAC_T158","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G99103VB\""},{"id":"GlycanIUPAC_T159","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G99103VB\""},{"id":"GlycanIUPAC_T160","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G99530XJ\""},{"id":"GlycanIUPAC_T161","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G99530XJ\""},{"id":"GlycanIUPAC_T162","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G64132OC\""},{"id":"GlycanIUPAC_T163","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G64132OC\""},{"id":"GlycanIUPAC_T164","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G96071SL\""},{"id":"GlycanIUPAC_T165","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G96071SL\""},{"id":"GlycanIUPAC_T166","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G11932TO\""},{"id":"GlycanIUPAC_T167","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G11932TO\""},{"id":"GlycanIUPAC_T168","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G71952HE\""},{"id":"GlycanIUPAC_T169","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G71952HE\""},{"id":"GlycanIUPAC_T170","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G40960ZM\""},{"id":"GlycanIUPAC_T171","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G40960ZM\""},{"id":"GlycanIUPAC_T172","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G99023OP\""},{"id":"GlycanIUPAC_T173","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G99023OP\""},{"id":"GlycanIUPAC_T174","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G75940FW\""},{"id":"GlycanIUPAC_T175","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G75940FW\""},{"id":"GlycanIUPAC_T176","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G05449DN\""},{"id":"GlycanIUPAC_T177","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G05449DN\""},{"id":"GlycanIUPAC_T178","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G12045NX\""},{"id":"GlycanIUPAC_T179","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G12045NX\""},{"id":"GlycanIUPAC_T180","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G23531GF\""},{"id":"GlycanIUPAC_T181","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G23531GF\""},{"id":"GlycanIUPAC_T182","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G83439GF\""},{"id":"GlycanIUPAC_T183","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G83439GF\""},{"id":"GlycanIUPAC_T184","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G38120XA\""},{"id":"GlycanIUPAC_T185","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G38120XA\""},{"id":"GlycanIUPAC_T186","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G09257XC\""},{"id":"GlycanIUPAC_T187","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G09257XC\""},{"id":"GlycanIUPAC_T188","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G67867AY\""},{"id":"GlycanIUPAC_T189","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G67867AY\""},{"id":"GlycanIUPAC_T190","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G70826LI\""},{"id":"GlycanIUPAC_T191","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G70826LI\""},{"id":"GlycanIUPAC_T192","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G01893YT\""},{"id":"GlycanIUPAC_T193","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G01893YT\""},{"id":"GlycanIUPAC_T194","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G57032UK\""},{"id":"GlycanIUPAC_T195","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G57032UK\""},{"id":"GlycanIUPAC_T196","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G82566JW\""},{"id":"GlycanIUPAC_T197","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G82566JW\""},{"id":"GlycanIUPAC_T198","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G03647LB\""},{"id":"GlycanIUPAC_T199","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G03647LB\""},{"id":"GlycanIUPAC_T200","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G30298YA\""},{"id":"GlycanIUPAC_T201","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G30298YA\""},{"id":"GlycanIUPAC_T202","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G12237BJ\""},{"id":"GlycanIUPAC_T203","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G12237BJ\""},{"id":"GlycanIUPAC_T204","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G35293BQ\""},{"id":"GlycanIUPAC_T205","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G35293BQ\""},{"id":"GlycanIUPAC_T206","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G56939XC\""},{"id":"GlycanIUPAC_T207","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G56939XC\""},{"id":"GlycanIUPAC_T208","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G57481VS\""},{"id":"GlycanIUPAC_T209","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G57481VS\""},{"id":"GlycanIUPAC_T210","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G12760VJ\""},{"id":"GlycanIUPAC_T211","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G12760VJ\""},{"id":"GlycanIUPAC_T212","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G78749LG\""},{"id":"GlycanIUPAC_T213","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G78749LG\""},{"id":"GlycanIUPAC_T214","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G18179BX\""},{"id":"GlycanIUPAC_T215","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G18179BX\""},{"id":"GlycanIUPAC_T216","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G97803IP\""},{"id":"GlycanIUPAC_T217","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G97803IP\""},{"id":"GlycanIUPAC_T218","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G98770PI\""},{"id":"GlycanIUPAC_T219","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G98770PI\""},{"id":"GlycanIUPAC_T220","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G48944LU\""},{"id":"GlycanIUPAC_T221","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G48944LU\""},{"id":"GlycanIUPAC_T222","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G68361HD\""},{"id":"GlycanIUPAC_T223","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G68361HD\""},{"id":"GlycanIUPAC_T224","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G57043GW\""},{"id":"GlycanIUPAC_T225","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G57043GW\""},{"id":"GlycanIUPAC_T226","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G68666JO\""},{"id":"GlycanIUPAC_T227","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G68666JO\""},{"id":"GlycanIUPAC_T228","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G52284HH\""},{"id":"GlycanIUPAC_T229","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G52284HH\""},{"id":"GlycanIUPAC_T230","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G48271RR\""},{"id":"GlycanIUPAC_T231","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G48271RR\""},{"id":"GlycanIUPAC_T232","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G28222XB\""},{"id":"GlycanIUPAC_T233","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G28222XB\""},{"id":"GlycanIUPAC_T234","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G69666WN\""},{"id":"GlycanIUPAC_T235","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G69666WN\""},{"id":"GlycanIUPAC_T236","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G00846QB\""},{"id":"GlycanIUPAC_T237","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G00846QB\""},{"id":"GlycanIUPAC_T238","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G34497XL\""},{"id":"GlycanIUPAC_T239","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G34497XL\""},{"id":"GlycanIUPAC_T240","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G83093ZM\""},{"id":"GlycanIUPAC_T241","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G83093ZM\""},{"id":"GlycanIUPAC_T242","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G07756TT\""},{"id":"GlycanIUPAC_T243","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G07756TT\""},{"id":"GlycanIUPAC_T244","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G26740FE\""},{"id":"GlycanIUPAC_T245","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G26740FE\""},{"id":"GlycanIUPAC_T246","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G32930YQ\""},{"id":"GlycanIUPAC_T247","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G32930YQ\""},{"id":"GlycanIUPAC_T248","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G75215RK\""},{"id":"GlycanIUPAC_T249","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G75215RK\""},{"id":"GlycanIUPAC_T250","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G98272YB\""},{"id":"GlycanIUPAC_T251","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G98272YB\""},{"id":"GlycanIUPAC_T252","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G71155WF\""},{"id":"GlycanIUPAC_T253","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G71155WF\""},{"id":"GlycanIUPAC_T254","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G56744IY\""},{"id":"GlycanIUPAC_T255","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G56744IY\""},{"id":"GlycanIUPAC_T256","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G38394RH\""},{"id":"GlycanIUPAC_T257","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G38394RH\""},{"id":"GlycanIUPAC_T258","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G11815AV\""},{"id":"GlycanIUPAC_T259","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G11815AV\""},{"id":"GlycanIUPAC_T260","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G62676XB\""},{"id":"GlycanIUPAC_T261","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G62676XB\""},{"id":"GlycanIUPAC_T262","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G96377XW\""},{"id":"GlycanIUPAC_T263","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G96377XW\""},{"id":"GlycanIUPAC_T264","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G99347BR\""},{"id":"GlycanIUPAC_T265","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G99347BR\""},{"id":"GlycanIUPAC_T266","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G70803WR\""},{"id":"GlycanIUPAC_T267","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G70803WR\""},{"id":"GlycanIUPAC_T268","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G88778DU\""},{"id":"GlycanIUPAC_T269","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G88778DU\""},{"id":"GlycanIUPAC_T270","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G07971EH\""},{"id":"GlycanIUPAC_T271","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G07971EH\""},{"id":"GlycanIUPAC_T272","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G95272JN\""},{"id":"GlycanIUPAC_T273","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G95272JN\""},{"id":"GlycanIUPAC_T274","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G55109ZG\""},{"id":"GlycanIUPAC_T275","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G55109ZG\""},{"id":"GlycanIUPAC_T276","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G71585SL\""},{"id":"GlycanIUPAC_T277","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G71585SL\""},{"id":"GlycanIUPAC_T278","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G07197CP\""},{"id":"GlycanIUPAC_T279","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G07197CP\""},{"id":"GlycanIUPAC_T280","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G17730NT\""},{"id":"GlycanIUPAC_T281","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G17730NT\""},{"id":"GlycanIUPAC_T282","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G34903LH\""},{"id":"GlycanIUPAC_T283","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G34903LH\""},{"id":"GlycanIUPAC_T284","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G65660GA\""},{"id":"GlycanIUPAC_T285","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G65660GA\""},{"id":"GlycanIUPAC_T286","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G48172IK\""},{"id":"GlycanIUPAC_T287","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G48172IK\""},{"id":"GlycanIUPAC_T288","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G20725CN\""},{"id":"GlycanIUPAC_T289","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G20725CN\""},{"id":"GlycanIUPAC_T290","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G50853HE\""},{"id":"GlycanIUPAC_T291","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G50853HE\""},{"id":"GlycanIUPAC_T292","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G18401GJ\""},{"id":"GlycanIUPAC_T293","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G18401GJ\""},{"id":"GlycanIUPAC_T294","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G89755ME\""},{"id":"GlycanIUPAC_T295","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G89755ME\""},{"id":"GlycanIUPAC_T296","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G58581FW\""},{"id":"GlycanIUPAC_T297","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G58581FW\""},{"id":"GlycanIUPAC_T298","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G84356OA\""},{"id":"GlycanIUPAC_T299","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G84356OA\""},{"id":"GlycanIUPAC_T300","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G48553NO\""},{"id":"GlycanIUPAC_T301","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G48553NO\""},{"id":"GlycanIUPAC_T302","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G86886IB\""},{"id":"GlycanIUPAC_T303","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G86886IB\""},{"id":"GlycanIUPAC_T304","span":{"begin":847,"end":850},"obj":"\"http://rdf.glycoinfo.org/glycan/G22655ST\""},{"id":"GlycanIUPAC_T305","span":{"begin":857,"end":860},"obj":"\"http://rdf.glycoinfo.org/glycan/G22655ST\""},{"id":"GlycanIUPAC_T306","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T307","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T308","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T309","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T310","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T311","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T312","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T313","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T314","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T315","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T316","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T317","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T318","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T319","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T320","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T321","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T322","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T323","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T324","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T325","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T326","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T327","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T328","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T329","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T330","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T331","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T332","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T333","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T334","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T335","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T336","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T337","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T338","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T339","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T340","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T341","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T342","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T343","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T344","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T345","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T346","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T347","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T348","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T349","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T350","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T351","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T352","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T353","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T354","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T355","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T356","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T357","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T358","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T359","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T360","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T361","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T362","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T363","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T364","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T365","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T366","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T367","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T368","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T369","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T370","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T371","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T372","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T373","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T374","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T375","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T376","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T377","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T378","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T379","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T380","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T381","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T382","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T383","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T384","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T385","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T386","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T387","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T388","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T389","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T390","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T391","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T392","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T393","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T394","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T395","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T396","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T397","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T398","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T399","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T400","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T401","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T402","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T403","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T404","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T405","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T406","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T407","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T408","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T409","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T410","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T411","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T412","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T413","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T414","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T415","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T416","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T417","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T418","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T419","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T420","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T421","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T422","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T423","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T424","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T425","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T426","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T427","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T428","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T429","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T430","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T431","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T432","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T433","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T434","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T435","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T436","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T437","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T438","span":{"begin":1219,"end":1225},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T439","span":{"begin":1234,"end":1240},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T440","span":{"begin":1488,"end":1494},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T441","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G49112ZN\""},{"id":"GlycanIUPAC_T442","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G50059AJ\""},{"id":"GlycanIUPAC_T443","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G76218YK\""},{"id":"GlycanIUPAC_T444","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G50102KR\""},{"id":"GlycanIUPAC_T445","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G10717VS\""},{"id":"GlycanIUPAC_T446","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G60524RK\""},{"id":"GlycanIUPAC_T447","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G84407TT\""},{"id":"GlycanIUPAC_T448","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G64717JT\""},{"id":"GlycanIUPAC_T449","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G45003TT\""},{"id":"GlycanIUPAC_T450","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G73923FP\""},{"id":"GlycanIUPAC_T451","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G78231MB\""},{"id":"GlycanIUPAC_T452","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G80487UG\""},{"id":"GlycanIUPAC_T453","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G29758MI\""},{"id":"GlycanIUPAC_T454","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G02671KD\""},{"id":"GlycanIUPAC_T455","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G57926TZ\""},{"id":"GlycanIUPAC_T456","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G41718FD\""},{"id":"GlycanIUPAC_T457","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G99840FL\""},{"id":"GlycanIUPAC_T458","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G64321UX\""},{"id":"GlycanIUPAC_T459","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G11231EG\""},{"id":"GlycanIUPAC_T460","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G62741TN\""},{"id":"GlycanIUPAC_T461","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G51576ZQ\""},{"id":"GlycanIUPAC_T462","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G66056LD\""},{"id":"GlycanIUPAC_T463","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G02768BF\""},{"id":"GlycanIUPAC_T464","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G26168RO\""},{"id":"GlycanIUPAC_T465","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G42890HL\""},{"id":"GlycanIUPAC_T466","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G17533VU\""},{"id":"GlycanIUPAC_T467","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G34306RG\""},{"id":"GlycanIUPAC_T468","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G88735KU\""},{"id":"GlycanIUPAC_T469","span":{"begin":1226,"end":1229},"obj":"\"http://rdf.glycoinfo.org/glycan/G82605UA\""},{"id":"GlycanIUPAC_T470","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G19151BJ\""},{"id":"GlycanIUPAC_T471","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G63727IH\""},{"id":"GlycanIUPAC_T472","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G05795KA\""},{"id":"GlycanIUPAC_T473","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G90812SJ\""},{"id":"GlycanIUPAC_T474","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G07124DB\""},{"id":"GlycanIUPAC_T475","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G20567HS\""},{"id":"GlycanIUPAC_T476","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G76159WX\""},{"id":"GlycanIUPAC_T477","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G40623UW\""},{"id":"GlycanIUPAC_T478","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G06447MP\""},{"id":"GlycanIUPAC_T479","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G62764VZ\""},{"id":"GlycanIUPAC_T480","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G21434YY\""},{"id":"GlycanIUPAC_T481","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G34267PK\""},{"id":"GlycanIUPAC_T482","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G30235PC\""},{"id":"GlycanIUPAC_T483","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G34820UC\""},{"id":"GlycanIUPAC_T484","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G95531HX\""},{"id":"GlycanIUPAC_T485","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G74672YG\""},{"id":"GlycanIUPAC_T486","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G54440FW\""},{"id":"GlycanIUPAC_T487","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G69182II\""},{"id":"GlycanIUPAC_T488","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G68961XX\""},{"id":"GlycanIUPAC_T489","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G11710CQ\""},{"id":"GlycanIUPAC_T490","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G70765DS\""},{"id":"GlycanIUPAC_T491","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G51661YR\""},{"id":"GlycanIUPAC_T492","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G18477VG\""},{"id":"GlycanIUPAC_T493","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G12337MH\""},{"id":"GlycanIUPAC_T494","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G40783MY\""},{"id":"GlycanIUPAC_T495","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G72867LN\""},{"id":"GlycanIUPAC_T496","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G79061OT\""},{"id":"GlycanIUPAC_T497","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G45970UX\""},{"id":"GlycanIUPAC_T498","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G93661NW\""},{"id":"GlycanIUPAC_T499","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G04988XL\""},{"id":"GlycanIUPAC_T500","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G85800UH\""},{"id":"GlycanIUPAC_T501","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G96338GZ\""},{"id":"GlycanIUPAC_T502","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G96296PU\""},{"id":"GlycanIUPAC_T503","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G59124WZ\""},{"id":"GlycanIUPAC_T504","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G57275GR\""},{"id":"GlycanIUPAC_T505","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G46105MZ\""},{"id":"GlycanIUPAC_T506","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G76001GO\""},{"id":"GlycanIUPAC_T507","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G89599ML\""},{"id":"GlycanIUPAC_T508","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G85872BD\""},{"id":"GlycanIUPAC_T509","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G69460YK\""},{"id":"GlycanIUPAC_T510","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G25240JV\""},{"id":"GlycanIUPAC_T511","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G80489OS\""},{"id":"GlycanIUPAC_T512","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G35726XK\""},{"id":"GlycanIUPAC_T513","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G11002JA\""},{"id":"GlycanIUPAC_T514","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G85388FO\""},{"id":"GlycanIUPAC_T515","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G20221JL\""},{"id":"GlycanIUPAC_T516","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G39026SP\""},{"id":"GlycanIUPAC_T517","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G66979UZ\""},{"id":"GlycanIUPAC_T518","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G68566EA\""},{"id":"GlycanIUPAC_T519","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G20255ZD\""},{"id":"GlycanIUPAC_T520","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G68860MF\""},{"id":"GlycanIUPAC_T521","span":{"begin":1480,"end":1483},"obj":"\"http://rdf.glycoinfo.org/glycan/G50413KD\""}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlyCosmos15-Glycan
{"project":"GlyCosmos15-Glycan","denotations":[{"id":"T1","span":{"begin":143,"end":149},"obj":"Glycan"},{"id":"T2","span":{"begin":1732,"end":1738},"obj":"Glycan"},{"id":"T3","span":{"begin":1849,"end":1855},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A4","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A5","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A6","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
Glycan-GlyCosmos
{"project":"Glycan-GlyCosmos","denotations":[{"id":"T1","span":{"begin":143,"end":149},"obj":"Glycan"},{"id":"T2","span":{"begin":1732,"end":1738},"obj":"Glycan"},{"id":"T3","span":{"begin":1849,"end":1855},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A4","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A2","pred":"glycosmos_id","subj":"T2","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A5","pred":"image","subj":"T2","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"},{"id":"A3","pred":"glycosmos_id","subj":"T3","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A6","pred":"image","subj":"T3","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlyCosmos15-UBERON
{"project":"GlyCosmos15-UBERON","denotations":[{"id":"T1","span":{"begin":619,"end":624},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000992"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlyCosmos15-Taxon
{"project":"GlyCosmos15-Taxon","denotations":[{"id":"T1","span":{"begin":0,"end":5},"obj":"Organism"},{"id":"T2","span":{"begin":98,"end":103},"obj":"Organism"},{"id":"T3","span":{"begin":603,"end":618},"obj":"Organism"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"9606"},{"id":"A3","pred":"db_id","subj":"T3","obj":"10029"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlyCosmos15-Sentences
{"project":"GlyCosmos15-Sentences","blocks":[{"id":"T1","span":{"begin":0,"end":97},"obj":"Sentence"},{"id":"T2","span":{"begin":98,"end":293},"obj":"Sentence"},{"id":"T3","span":{"begin":294,"end":436},"obj":"Sentence"},{"id":"T4","span":{"begin":437,"end":502},"obj":"Sentence"},{"id":"T5","span":{"begin":503,"end":802},"obj":"Sentence"},{"id":"T6","span":{"begin":803,"end":964},"obj":"Sentence"},{"id":"T7","span":{"begin":965,"end":1152},"obj":"Sentence"},{"id":"T8","span":{"begin":1153,"end":1241},"obj":"Sentence"},{"id":"T9","span":{"begin":1242,"end":1441},"obj":"Sentence"},{"id":"T10","span":{"begin":1442,"end":1677},"obj":"Sentence"},{"id":"T11","span":{"begin":1678,"end":2032},"obj":"Sentence"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
GlyCosmos15-FMA
{"project":"GlyCosmos15-FMA","denotations":[{"id":"T1","span":{"begin":195,"end":204},"obj":"Body_part"},{"id":"T2","span":{"begin":619,"end":624},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"FMA:63836"},{"id":"A2","pred":"db_id","subj":"T2","obj":"FMA:7209"}],"namespaces":[{"prefix":"FMA","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
NCBITAXON
{"project":"NCBITAXON","denotations":[{"id":"T1","span":{"begin":0,"end":5},"obj":"OrganismTaxon"},{"id":"T2","span":{"begin":98,"end":103},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":603,"end":618},"obj":"OrganismTaxon"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"9606"},{"id":"A2","pred":"db_id","subj":"T2","obj":"9606"},{"id":"A3","pred":"db_id","subj":"T3","obj":"10029"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}
Anatomy-UBERON
{"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":619,"end":624},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000992"}],"text":"Human alpha-N-acetylgalactosaminidase: site occupancy and structure of N-linked oligosaccharides.\nHuman alpha-N-acetylgalactosaminidase (alpha-GalNAc; also known as alpha-galactosidase B) is the lysosomal exoglycohydrolase that cleaves alpha-N-acetylgalactosaminyl moieties in glycoconjugates. Mutagenesis studies indicated that the first five (N124, N177, N201, N359, and N385) of the six potential N-glycosylation sites were occupied. Site 3 occupancy was important for enzyme function and stability. Characterization of the N-linked oligosaccharide structures on the secreted enzyme overexpressed in Chinese hamster ovary cells revealed highly heterogeneous structures consisting of complex (approximately 53%), hybrid (approximately 12%), and high mannose-type (approximately 33%) oligosaccharides. The complex structures were mono-, bi-, 2,4-tri-, 2,6-tri-, and tetraantennary, among which the biantennary structures were most predominant (approximately 53%). Approximately 80% of the complex oligo-saccharides had a core-region fucose and 50% of the complex oligosaccharides were sialylated exclusively with alpha-2,3-linked sialic acid residues. The majority of hybrid type oligo-saccharides were GalGlcNAcMan(6)GlcNAc-Fuc(0-1)GlcNAc. Approximately 54% of the hybrid oligosaccharide were phosphorylated and one-third of these structures were further sialylated, the latter representing unique phosphorylated and sialylated structures. Of the high mannose oligosaccharides, Man(5-7)GlcNAc(2) were the predominant species (approximately 90%) and about 50% of the high mannose oligosaccharides were phosphorylated, exclusively as monoesters whose positions were determined. Comparison of the oligosaccharide structures of alpha-GalNAc and alpha-galactosidase A, an evolutionary-related and highly homologous exoglycosidase, indicated that alpha-GalNAc had more completed complex chains, presumably due to differences in enzyme structure/domains, rate of biosynthesis, and/or aggregation of the overexpressed recombinant enzymes."}